loading page

Association study between herpes zoster reporting and mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273)
  • +3
  • Laure-Hélène Préta,
  • Adrien Contejean,
  • Francesco Salvo,
  • Jean-Marc Tréluyer,
  • Caroline Charlier,
  • Laurent Chouchana
Laure-Hélène Préta
Assistance Publique - Hopitaux de Paris
Author Profile
Adrien Contejean
Assistance Publique - Hopitaux de Paris
Author Profile
Francesco Salvo
Université de Bordeaux
Author Profile
Jean-Marc Tréluyer
Author Profile
Caroline Charlier
Assistance Publique - Hopitaux de Paris
Author Profile
Laurent Chouchana
Hospital Cochin
Author Profile

Abstract

Several cases of herpes zoster (HZ) following mRNA COVID-19 vaccination (BNT162b2 and mRNA-1273) have been reported, and first epidemiological evidences suggest an increased risk. We used the worldwide pharmacovigilance database VigiBase to describe HZ cases following mRNA COVID-19 vaccination. We performed disproportionality analyses (case/non-case statistical approach) to assess the relative risk of HZ reporting in mRNA COVID-19 vaccine recipients compared to influenza vaccine recipients and according to patient age. Until 30th June 2021, of 716,928 reports about mRNA COVID-19 vaccines, we found 7,728 HZ cases. When compared to influenza vaccines, mRNA COVID-19 vaccines were associated with a significantly higher reporting of HZ (reporting odds-ratio 1.9, 95%CI [1.8-2.1]). Furthermore, we found a reduced risk of reporting HZ among under 40 year-old persons compared to older persons (reporting odds-ratio 0.39, 95%CI [0.36-0.41]). For the first time, we could assess at a global level the risk of HZ after mRNA COVID-19 vaccination.
25 Oct 2021Submitted to British Journal of Clinical Pharmacology
26 Oct 2021Submission Checks Completed
26 Oct 2021Assigned to Editor
15 Dec 2021Reviewer(s) Assigned
30 Dec 2021Review(s) Completed, Editorial Evaluation Pending
14 Jan 2022Editorial Decision: Revise Minor
04 Feb 20221st Revision Received
07 Feb 2022Submission Checks Completed
07 Feb 2022Assigned to Editor
07 Feb 2022Review(s) Completed, Editorial Evaluation Pending
10 Feb 2022Editorial Decision: Accept
28 Feb 2022Published in British Journal of Clinical Pharmacology. 10.1111/bcp.15280